Werewolf Therapeutics, Inc. HOWL
We take great care to ensure that the data presented and summarized in this overview for Werewolf Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HOWL
View all-
Mpm Asset Management LLC Cambridge, MA4.28MShares$20.9 Million11.32% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA3.01MShares$14.7 Million0.96% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3MShares$14.6 Million0.04% of portfolio
-
Bio Impact Capital LLC Cambridge, MA2.39MShares$11.7 Million2.53% of portfolio
-
Bank Of America Corp Charlotte, NC1.88MShares$9.18 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X01.69MShares$8.24 Million0.01% of portfolio
-
Rubric Capital Management LP New York, NY1.62MShares$7.91 Million0.36% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.11MShares$5.4 Million0.0% of portfolio
-
Monashee Investment Management LLC Boston, MA890KShares$4.34 Million0.79% of portfolio
-
Eagle Health Investments LP Greenwich, CT700KShares$3.42 Million0.84% of portfolio
Latest Institutional Activity in HOWL
Top Purchases
Top Sells
About HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at HOWL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 06
2023
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,853,000
+24.53%
|
$3,706,000
$2.21 P/Share
|
|
Jan 12
2022
|
Cynthia Seidel Dugan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,731
+11.28%
|
$119,193
$3.17 P/Share
|
|
Dec 30
2021
|
Reid Leonard Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,102
+50.0%
|
$14,102
$1.56 P/Share
|
|
Dec 15
2021
|
Reid Leonard Chief Operating Officer |
SELL
Open market or private sale
|
Indirect |
3,000
-1.2%
|
$39,000
$13.68 P/Share
|
|
Jun 16
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
9,285
+0.22%
|
$120,705
$13.37 P/Share
|
|
Jun 15
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
7,958
+0.19%
|
$95,496
$12.95 P/Share
|
|
Jun 14
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
306,055
+6.68%
|
$3,672,660
$12.75 P/Share
|
|
May 04
2021
|
Mpm Bio Ventures 2014, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
125,759
+3.8%
|
$2,012,144
$16.0 P/Share
|
|
May 04
2021
|
Mpm Bio Ventures 2014, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,062,239
+34.98%
|
-
|
|
May 04
2021
|
Ansbert Gadicke > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
245,000
+3.54%
|
$3,920,000
$16.0 P/Share
|
|
May 04
2021
|
Ansbert Gadicke > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
5,965,775
+33.17%
|
-
|
|
May 04
2021
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,715,000
+25.3%
|
$27,440,000
$16.0 P/Share
|
|
May 04
2021
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
2,253,583
+50.0%
|
-
|
|
May 04
2021
|
Luke Evnin |
BUY
Open market or private purchase
|
Indirect |
150,799
+3.4%
|
$2,412,784
$16.0 P/Share
|
|
May 04
2021
|
Luke Evnin |
BUY
Conversion of derivative security
|
Indirect |
3,671,965
+32.14%
|
-
|
|
May 04
2021
|
Hbm Healthcare Investments (Cayman) Ltd. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
625,995
+50.0%
|
-
|
|
May 04
2021
|
Upmc > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,097,756
+34.98%
|
-
|
|
May 04
2021
|
Longwood Fund Iii Gp, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
250,000
+12.97%
|
$4,000,000
$16.0 P/Share
|
|
May 04
2021
|
Longwood Fund Iii Gp, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,427,082
+34.98%
|
-
|
|
May 04
2021
|
Arkin Bio Ventures 2 L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
400,000
+16.35%
|
$6,400,000
$16.0 P/Share
|